Nuvation Bio Reports $13.1 Million Revenue in Q3 2025, Despite $55.8 Million Net Loss

Nuvation Bio Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenues of $13.1 million for the third quarter, a substantial increase from $727,000 in the same period last year. This growth was primarily driven by product revenue of $7.7 million from the U.S. sales of its oncology drug, IBTROZI, which was launched in June 2025, alongside collaboration and license agreement revenues that rose to $5.4 million from $727,000 in the prior year. For the nine months ended September 30, 2025, total revenues reached $21 million, compared to $2.2 million in the same period of 2024.

Despite the increase in revenue, Nuvation Bio reported a net loss of $55.8 million for the third quarter, slightly higher than the $41.2 million loss recorded in the same quarter of 2024. The company's operating expenses also rose significantly, totaling $66.2 million for the quarter, compared to $47.3 million a year earlier. This increase was attributed to higher research and development costs, which amounted to $28.8 million, and selling, general, and administrative expenses, which reached $37.4 million. The company’s accumulated deficit as of September 30, 2025, stood at approximately $1.08 billion.

In terms of strategic developments, Nuvation Bio completed the acquisition of AnHeart Therapeutics in April 2024, which has contributed to its product pipeline and revenue streams. The company is actively pursuing regulatory approvals for its product candidates, including taletrectinib, which has received approvals in both Japan and China. The company also announced the enrollment of the first patient in the Phase 3 TRUST-IV study for taletrectinib, indicating ongoing commitment to advancing its clinical programs.

Operationally, Nuvation Bio reported a cash position of $549 million as of September 30, 2025, which includes cash, cash equivalents, and marketable securities. The company expects this liquidity to support its operations for at least the next 12 months. The workforce has expanded, with an increase in headcount contributing to higher personnel-related costs. The company anticipates continued investment in research and development, which is expected to drive future growth but may also lead to increased operating losses in the near term.

Looking ahead, Nuvation Bio's management remains focused on advancing its clinical trials and product commercialization efforts. The company acknowledges the need for substantial additional funding to support its growth strategy and ongoing operations, particularly as it navigates the complexities of drug development and regulatory approval processes. The outlook remains cautiously optimistic, with expectations of continued revenue growth from product sales and collaboration agreements as its product candidates progress through clinical development.